Tyr651
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr651  -  CD229 (human)

Site Information
EIPEsPTyENFT___   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455757

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 ) , mutation of modification site ( 2 )
Relevant cell line - cell type - tissue:
COS (fibroblast) ( 2 ) , Jurkat (T lymphocyte) ( 1 , 2 )

Upstream Regulation
Treatments:
antibody ( 2 ) , vanadate ( 2 )

Downstream Regulation
Effects of modification on CD229:
molecular association, regulation ( 2 ) , receptor internalization, altered ( 2 )
Induce interaction with:
GRB2 (human) ( 2 )

References 

1

Zhou J (2011) CST Curation Set: 12314; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

2

Martín M, Del Valle JM, Saborit I, Engel P (2005) Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. J Immunol 174, 5977-86
15879090   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.